ABP 710 FDA Approval Status
FDA Approved: No
Brand name: ABP 710
Generic name: biosimilar infliximab
Company: Amgen Inc.
Treatment for: Rheumatoid Arthritis, Plaque Psoriasis, Crohn's Disease, Maintenance, Ulcerative Colitis, Psoriatic Arthritis, Ankylosing Spondylitis
ABP 710 (biosimilar infliximab) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade (infliximab) in development for the treatment of rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis.
Development timeline for ABP 710
| Date | Article |
|---|---|
| Dec 17, 2018 | Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
